Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor polyneuropathie bij MGUS.

Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017; 92(5): 838–50
Jaccard A. Monoclonal IgM and neuropathy: not always anti-MAG. Blood 2020; 136:2366-2367
Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996; 40(5): 792–5
Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002; 249(10): 1370–7
Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in antimag polyneuropathy. Neurology. 2008; 71(21): 1742–4
Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009; 65(3): 286–93
Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatr. 2003; 74(4): 485–9
D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017; 176(5): 728–42

Ga terug naar de homepage PN geassocieerd met MGUS of lees meer hierover:

Ga terug naar de homepage MGUS.